ByronLLamMD

Ophthalmology • Miami, FL

Neuro-Ophthalmology, Retinal Disease

Professor, Ophthalmology, University of Miami School of Medicine

Join to view full profile

Dr. Lam is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lam's full profile

Already have an account?

Office
900 NW 17th St
# M851
Miami, FL 33136
Phone+1 305-326-6031

Fax+1 305-243-8470

Education & Training

University of Illinois College of Medicine at ChicagoFellowship, Electrophysiology, Hereditary Retinal Disease, 1992 - 1992
University of Miami/Jackson Health SystemFellowship, Neuro-Ophthalmology, 1991 - 1991
University of Iowa Hospitals and ClinicsResidency, Ophthalmology, 1987 - 1990
Swedish HospitalInternship, Transitional Year, 1986 - 1987
Boston University School of MedicineClass of 1986

Certifications & Licensure

FL State Medical License 1991 - 2026
AR State Medical License 1991 - 1996
IL State Medical License 1986 - 1993
IA State Medical License 1987 - 1992
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Super Doctor SuperDoctors.com
Fellow (FAAO) American Academy of Ophthalmology

Clinical Trials

Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy Start of enrollment: 2011 Jun 16
Completed
Phase 1, Phase 2
Clinical and Genetic Characterization of Individuals With Achromatopsia Start of enrollment: 2013 Jun 01
Completed
New Enrollment Post-Approval Study of the Argus® II Retinal Prosthesis System Start of enrollment: 2014 Jan 01
Terminated
Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients Start of enrollment: 2012 Jul 11
Completed
Choroideremia Gene Therapy Clinical Trial Start of enrollment: 2015 Sep 01
Completed
Phase 2
Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial) Start of enrollment: 2017 Aug 03
Active, not recruiting
Phase 1, Phase 2
Biomechanics of Optic Neuropathy Start of enrollment: 2016 Sep 01
Terminated
PRIMA US-Feasibility Study in Atrophic Dry AMD Start of enrollment: 2018 Apr 26
Active, not recruiting
Not Applicable
Natural History Study of CEP290-Related Retinal Degeneration Start of enrollment: 2017 Dec 17
Completed
Oral N-acetylcysteine for Retinitis Pigmentosa Start of enrollment: 2023 Oct 11
Recruiting
Phase 3
Roles: Contact
A Trial to Determine the Efficacy and Safety of Presendin in IIH Start of enrollment: 2022 Nov 18
Terminated
Phase 3
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Extreme Phenotypic Variability of-Related Disorders in Hearing Loss.
Maria T Bernardi, Memoona Ramzan, Laura Calderon, Franco Salvatore, Maria Agustina De Rosa
Advanced Genetics. 2024-12-01
To do or not to do: Large-dose steroid treatment for severe vision loss secondary to compressive inflammatory optic neuropathy in the setting of invasive fungal sinusi...
Charissa H Tan, Benjamin I Meyer, Colin Kim, Mohammed Raja, Jaylou M Velez Torres
American Journal of Ophthalmology Case Reports. 2024-12-01
Severe visual loss from concurrent fulminant idiopathic intracranial hypertension and malignant arterial hypertension: Prompt suspicion matters.
Bashaer Aldhahwani, Serena M Shah, Hong Jiang, Byron L Lam
American Journal of Ophthalmology Case Reports. 2024-12-01

Journal Articles

Longitudinal Associations Between Visual Impairment and Cognitive Functioning
Byron Lam, MD, JAMA
Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients with Autosomal Dominant Retinitis Pigmentosa
David G Birch, Michael P Teske, Richard G Weleber, Robert Lindblad, Byron L Lam, Judith Warner, Gary Edd Fish, Neal L Sklaver, Mark E Pennesi, John Heckenlively, Paul ..., JAMA

Press Mentions

Q&A: What Is Your Role in Managing Depression in Patients with IRD?October 28th, 2024
Five Gene Therapy Trial Readouts to Watch in the First Half of 2023January 20th, 2023
Approvability of GenSight’s Gene Therapy for a Rare Eye Disease Premature to Judge Based on Existing Phase III ResultsFebruary 5th, 2021
Join now to see all

Professional Memberships

American Academy of Ophthalmology - AAO
Fellow